Pharmacogenetics for type 2 diabetes: practical considerations for study design.

Item

http://www.wikidata.org/entity/Q42599734

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@en

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@nl

type

Item

label

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@en

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@nl

prefLabel

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@en

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@nl

P1476

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

@en

P2093

Adrian Vella

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

Sequence variation in PPARG may underlie differential response to troglitazone.

P304

705-709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/193229680900300415

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41418729

http://www.w3.org/2001/XMLSchema#string

P698

20144317

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2769969

http://www.w3.org/2001/XMLSchema#string